Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Eli Lilly & Co on Monday unveiled a new multi-dose form of its blockbuster obesity drug Zepbound, allowing patients to ...

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for ...

The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...

Eli Lilly has rolled out a multi-dose KwikPen version of tirzepatide, marketed as Zepbound, for chronic weight management—signaling a packaging update for one of the obesity market’s fastest-expanding ...

The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer ...

Eli Lilly & Co. (LLY) on Monday announced a price cut for its blockbuster weight-loss drug, Zepbound, as it looks to match a similar price cut announced by rival Novo Nordisk AS (NVO). Lilly announced ...

Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...

Eli Lilly said the drug will be available at the same self-pay price in either the multi-dose pen or single-dose vial format, starting at $299 a month for the 2.5-milligram starter dose through ...